Johns Hopkins Medicine Acquires Naviscan' PEM | Naviscan, Inc.
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Healthcare Company News Naviscan, Inc. Johns Hopkins Medicine Acquires Naviscan' PEM

Johns Hopkins Medicine Acquires Naviscan' PEM

Company News - Naviscan, Inc.

Johns Hopkins Medicine has become the latest academic medical center to acquire the Naviscan Positron Emission Mammography (PEM) scanner for Novel Radiotracer Research.

The device will be utilized by Richard Wahl, M.D., F.A.C.R, Professor of Radiology and Nuclear Medicine at the Johns Hopkins University School of Medicine, in pre-clinical and translational research for the development of novel radiotracers.

"As the use of Naviscan's organ-specific PET imaging technology continues to be used in cutting-edge breast cancer research and clinical patient management, Naviscan is also developing its use in new clinical applications. As a result, the development and clinical validation of novel radiotracers is essential," said Paul J. Mirabella, Chairman and CEO, Naviscan, Inc.

Dr. Wahl patented the technology which enabled Naviscan to develop the first and only FDA-cleared PET-guided biopsy accessory, known as Stereo Navigator. Naviscan obtained an exclusive license to this patent, which Wahl developed while he was at the University of Michigan.

Other academic medical centers utilizing Naviscan 's PEM technology include University of Cincinnati, Baylor University, M.D. Anderson, University of Chicago, and the Boston University Medical Center.

Source: Naviscan

You can discuss about Naviscan and its products & services in the Naviscan User Group